skip to content
Primary navigation


DrugModeriba™ (ribavirin) [AbbVie Inc.]

June 2014

Therapeutic area - Hepatitis C

Approval criteria

Patients can not take metoclopramide oral tablets or oral solution.

FDA approved indication

  • Patient must have a diagnosis of hepatitis C AND
  • Prescriber must documentation of genotype (to determine length of treatment) AND
  • Prescriber must provide a compelling reason why generic ribavirin cannot be used

Quantity/Therapy limitations

  • Genotype 1, 4 = 48 weeks of therapy
  • Genotype 2, 3 = 24 weeks of therapy
  • HIV coinfection = 48 weeks of therapy

Background information

Moderiba™ (ribavirin, USP) is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in adults with compensated liver disease not previously treated with interferon alpha, and in CHC patients coinfected with HIV.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top